Browsing Tag
CAR-T therapy
15 posts
Glioblastoma trial for MT027 moves forward as T-MAXIMUM debuts allogeneic cell therapy in CNS
T-MAXIMUM wins FDA clearance for MT027 in glioblastoma. Read how its non-viral, off-the-shelf CAR-T may reshape solid tumor cell therapy development.
Is Vivacta Bio’s GT801 the next frontier in CAR-T therapy? Early human data reveal scalable, chemo-free promise
Vivacta Bio’s GT801 shows early promise as a repeat-dose in vivo CAR-T therapy for lymphoma. Find out how this could reshape immunotherapy delivery.
Is Johnson & Johnson’s CARVYKTI shifting the multiple myeloma treatment curve?
Johnson & Johnson’s CARVYKTI shows 80% 30-month remission in earlier-line multiple myeloma. See how CARTITUDE-4 could change the treatment landscape.
Why Imugene is using a virus to “mark” tumors for CAR-T attack—and what JW Therapeutics brings to the table
Find out how Imugene and JW Therapeutics plan to make solid tumors respond to CD19 CAR-T therapy using an oncolytic virus strategy.
Cabaletta Bio’s rese-cel CAR-T data at ESGCT 2025 reveal biologic activity without preconditioning in autoimmune disease
Cabaletta Bio’s ESGCT 2025 rese-cel data show early CAR-T activity without chemotherapy preconditioning — see how this could redefine autoimmune therapy.
Can immune-based doublets push CAR-T and bispecifics into earlier multiple myeloma treatment lines?
Can immune-based doublets like TECVAYLI and DARZALEX FASPRO push CAR-T and bispecifics into earlier multiple myeloma treatment lines?
Hemogenyx Pharmaceuticals stock jumps after third patient in CAR-T AML trial shows safety and early efficacy
Hemogenyx Pharmaceuticals (LSE: HEMO) stock jumps 24% after third patient treated in CAR-T AML trial shows safety and early efficacy.
Can faster CAR-T turnaround save more lives under the UK’s new point-of-care manufacturing rules?
The UK’s new point-of-care rules promise faster CAR-T therapy turnaround—find out how this could improve cancer survival rates and expand NHS access.
Innovent Biologics, IASO Bio strengthen collaboration with equity investment and licensing deal
Innovent Biologics, Inc. (HKEX: 01801), a globally recognized biopharmaceutical company, and IASO Biotechnology, a leader in innovative cell…
Poseida Therapeutics gets FDA orphan drug designation for P-BCMA-ALLO1 in multiple myeloma
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a trailblazer in the field of clinical-stage cell and gene therapy, has achieved…